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To image hypoxia-inducible factor-1 (HIF-1)-active tumors, we
previously developed a chimeric protein probe ([123 ⁄ 125I]IPOS) that
is degraded in the same manner as HIF-1a under normoxic condi-
tions. In the present study, we aim to show that the accumulation
of radioiodinated POS reflects the expression of HIF-1. In vivo
single-photon emission computed tomography (SPECT) ⁄X-ray CT
(CT) imaging, autoradiography, and double-fluorescent immuno-
staining for HIF-1a and pimonidazole (PIMO) were carried out 24 h
after the injection of [125I]IPOS. Tumor metabolite analysis was also
carried out. A tumor was clearly visualized by multi-pinhole, high-
resolution SPECT ⁄CT imaging with [125I]IPOS. The obtained images
were in accordance with the corresponding autoradiograms and
with the results of ex vivo biodistribution. A metabolite analysis
revealed that 77% of the radioactivity was eluted in the macromo-
lecular fraction, suggesting that the radioactivity mainly existed as
[125I]IPOS in the tumors. Immunohistochemistry revealed that the
HIF-1a-positive areas and PIMO-positive areas were not always
identical, only some of the regions were positive for both markers.
The areas showing [125I]IPOS accumulation were positively and
significantly correlated with the HIF-1a-positive areas (R = 0.75,
P < 0.0001). The correlation coefficient between [125I]IPOS-accumu-
lated areas and HIF-1a-positive areas was significantly greater than
that between the [125I]IPOS-accumulated areas and the PIMO-
positive areas (P < 0.01). These findings indicate that [125I]IPOS
accumulation reflects HIF-1 expression. Thus, [123 ⁄ 125I]IPOS can
serve as a useful probe for the molecular imaging of HIF-1-active
tumors. (Cancer Sci 2011; 102: 2090–2096)
T he expansion of a tumor mass implies the development ofcancer cells that are distant from blood vessels. Cells
outgrow their vascular supply, leading to the lowering of oxygen
partial pressure below physiologic levels (i.e., hypoxia).
Hypoxia-inducible factor-1 (HIF-1) is a key transcriptional
regulator in response to hypoxia.(1) Overexpression of HIF-1 has
been indicated in over 70% of human cancers (e.g. breast, pros-
tate, brain, lung, head and neck cancers) and their metastases
compared to that of adjacent normal tissue.(2) Clinical studies
associate the hypoxic status of a tumor with bad prognosis and
resistance to chemotherapy and radiotherapy.(3) Furthermore,
several HIF-1 inhibitors have been developed to inhibit tumor
growth and to overcome resistance to therapies.(4) Thus, non-
invasive imaging of HIF-1-active regions in a tumor provides
useful information for qualitative cancer diagnosis, cancer
therapy, and improving the effectiveness of HIF-1 inhibitors.
The expression of HIF-1 in tumors has been shown to be
affected by the microenvironment in each tumor, resulting in
heterogeneous HIF-1 tumor activity and expression.(5) More-
over, HIF-1 has been reported to be expressed even in a small
tumor spheroid (<1 mm in diameter).(6) Therefore, a high spatial
resolution device was required for the accurate imaging of
HIF-1-expressed regions. Several techniques to improve spatial
resolution, such as depth-of-interaction scintillators, image
reconstruction using time-of-flight information, and multi-
pinhole collimators, have recently been developed(7–10) and
incorporated into commercially available PET and single-photon
emission computed tomography (SPECT) systems. These
modalities enable the detailed visualization of intratumoral HIF-
1 expression in both animal models and humans.
Hypoxia-inducible factor-1 is composed of two subunits,
HIF-1a and HIF-1b. The former is rapidly degraded by the
ubiquitin–proteasome pathway under normoxic conditions, but
it is stabilized under hypoxic conditions and regulates HIF-1
transcriptional activity. The proteasomal degradation of HIF-1a
occurs through protein hydroxylation on proline residues in the
oxygen-dependent degradation domain (ODD) of HIF-1a.(11,12)
Thus, it is expected that probes containing the ODD and that are
degraded in manner similar to HIF-1a can evaluate HIF-1 activ-
ity in vivo.
Based on the above concept, we recently developed a protein
in which the protein transduction domain (PTD)(13) and a
monomeric streptavidin (SAV) are fused to the ODD. We
also synthesized a radiolabeled biotin derivative, (3-[123 ⁄ 125I]
iodobenzoyl)norbiotinamide ([123 ⁄ 125I]IBB) and conjugated the
chimeric protein, PTD-ODD-SAV (POS), and [123 ⁄ 125I]IBB to pro-
duce [123 ⁄ 125I]IBB-POS ([123 ⁄ 125I]IPOS). POS was degraded in an
oxygen-dependent manner, and a clear tumor image was obtained
by planar imaging at 24 h after the injection of [123I]IPOS. The
intratumoral distribution of [125I]IPOS corresponded to the hypoxic
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areas. However, direct comparison between the area showing
[125I]IPOS accumulation and HIF-1a expression was not carried out
in the previous study.(14) Moreover, the 3D distribution of HIF-1-
active regions in tumors has not been extensively evaluated in vivo.
We then compared [125I]IPOS distribution to HIF-1 expression by
autoradiographic and immunohistochemical studies in the present
study. Moreover, we attempted to image the detailed intratumoral
distribution of [125I]IPOS, which potentially reflects the heteroge-
neous expression of HIF-1, using a multi-pinhole, high-resolution
small animal SPECT. The purpose of the present study is to reveal
whether [123 ⁄ 125I]IPOS can be used to visualize HIF-1-active
regions in a tumor.
Materials and Methods
Animal model. Animal studies were carried out in accordance
with our institutional guidelines, and the experimental proce-
dures were approved by the Kyoto University Animal Care
Committee (Kyoto, Japan) and the Ethical Committee for
Animal Experiments of the National Cancer Center (Kashiwa,
Japan). Five-week-old female C3H ⁄He mice were purchased
from Japan SLC (Hamamatsu, Japan) and kept at a constant
ambient temperature under a 12-h light ⁄dark cycle with free
access to food and water. FM3A mouse mammary carcinoma
cells were cultured and s.c. implanted in the right thigh as
described in previous reports.(14,15) Approximately 2 weeks after
the implantation, the mice were subjected to a tracer study. The
average diameter of the tumors was 10 mm.
Radiosynthesis of [125I]IPOS. POS was overexpressed in Esc-
herichia coli and purified, as described in a previous report.(14)
Purified POS was dissolved in Tris–HCl buffer (pH 8.0).
Sodium [125I]iodide was purchased from PerkinElmer Life
and Analytical Sciences (Boston, MA, USA). As described in a
previous report,(14) [125I]IBB was synthesized with a radiochem-
ical yield of 40–50%. [125I]IPOS was synthesized by incubation
of [125I]IBB and POS for 1 h followed by purification using
Sephadex G50 columns (GE Healthcare Bioscience, Uppsala,
Sweden). Using [125I]IBB as a starting material, [125I]IPOS was
obtained with a radiochemical yield of >85% and a radiochemi-
cal purity of >95%.
In vivo and ex vivo SPECT ⁄CT imaging. Two FM3A-bearing
mice were used in this study. They were i.v. injected with
[125I]IPOS (30 lg, 23 MBq), and 24 h later, CT and SPECT
images were acquired under 1.5% isoflurane anesthesia. A
SPECT ⁄CT combined scanner was used to acquire sectional
images; the scanner had four detectors equipped with tungsten-
based, multiplexing multi-pinhole collimators dedicated for
small animal imaging (NanoSPECT ⁄CT; Bioscan, Washington,
DC, USA).
First, CT scans were carried out under the following condi-
tions: tube voltage, 45 kV; tube current, 177 lA; and tube
current-time product (the product of tube current and scan time),
32 mAs. The obtained CT data were reconstructed using a cone-
beam filtered back-projection method with InVivoScope
(Bioscan) postprocessing software.
The SPECT scans were then carried out. In the SPECT sys-
tem, each collimator had nine pinholes, each with a diameter of
1.4 mm and a cylindric field of view of 32 mm in diame-
ter · 16 mm in length. The axial field of view was extended
using a step-and-shoot helical SPECT with a user-defined range
of up to 230 mm, based on the region to be imaged. The energy
peak for the camera was set to 28 keV, and the energy window
was set to peak energy ± 30%, that is, 20–36 keV. In vivo
SPECT acquisition was carried out in six steps over 90 (300 s
per step), with four detectors covering 360. The total acquisi-
tion time to scan a range of 71.9 mm was 90 min per mouse.
The acquired SPECT data were reconstructed with HiSPECT
postprocessing software (SciVis, Go¨ettingen, Germany) by an
ordered subsets–expectation maximization algorithm designed
for multiplexing multi-pinhole reconstruction.
Both SPECT and CT images were automatically coregistered
because both systems shared the same axis of rotation, allowing
for the combination of scintigraphic and anatomic information
in all tomographic scans in three different spatial axes.
After in vivo imaging, the mice were killed and the tumors
were carefully excised. The ex vivo SPECT image of each tumor
was acquired for 60 min with an acquisition time of 600 s per
projection. The tumors were then frozen and cut into 6-lm-thick
sections for H&E staining and into 20-lm-thick sections for
autoradiography. The sections were prepared in the same direc-
tion of the SPECT slice. The section corresponding to the
SPECT image was selected according to the slice thickness and
used for autoradiography.
Ex vivo biodistribution, autoradiography, and immuno-
histochemistry. FM3A-bearing mice (n = 5) were i.v. injected
with [125I]IPOS (30 lg, 3.2 MBq); 22 h later, they were i.p.
injected with pimonidazole (PIMO; 60 mg ⁄kg). After another
2 h, the mice were killed. Whole organ specimens were immedi-
ately removed, weighed, and their radioactivity was measured
with an auto-well gamma counter (Wizard 1480; PerkinElmer,
Waltham, MA, USA). The results were expressed in terms of the
percent injected dose per gram of tissue (%ID ⁄g). The tumors
were removed and divided into two parts. The radioactivity of
one part was counted, and the other part was immediately
frozen. After freezing, 10-lm-thick sections of tumor were
prepared with a cryomicrotome (CM1900; Leica Microsystems,
Wetzlar, Germany). Two sections were prepared from each
tumor, and autoradiograms of these sections were obtained,
according to a previously described method,(16,17) but with the
following minor modification: a BAS5000 scanner was used
instead of a BAS3000 scanner (both scanners; Fuji Photo Film,
Tokyo, Japan). The same slides used in the autoradiographic
study were subjected to dual fluorescent immunostaining for
HIF-1a and PIMO.(15,18) Adjacent sections on each autoradio-
gram were stained with H&E to identify the necrotic regions.
Size-exclusion analysis of radioactive compounds in
tumors. After an i.v. injection of [125I]IPOS (30 lg, 4.4 MBq),
FM3A-bearing mice (n = 3) were housed in metabolic cages
(Metabolica; Sugiyama-Gen, Tokyo, Japan) for 24 h for the
collection of urine and feces. Subsequently, the mice were
killed. Extracts from the tumors and the feces were prepared by
using a previously reported method,(15,18,19) with slight modifi-
cations. In brief, the tumors and feces were homogenized, and
the preparations were centrifuged at 5000g at 4C for 30 min.
The supernatants and urine were analyzed by size-exclusion
chromatography (PD-10; GE Healthcare Bioscience). In addi-
tion, aliquots of the supernatants from the tumors were analyzed
by size-exclusion high-performance liquid chromatography
(HPLC; TSKgel SuperSW2000; 4.6 · 300 mm; Tosoh, Tokyo,
Japan) (100 mM phosphate buffer [pH 6.8], 0.2 mL ⁄min).
Image analyses of autoradiograms and immunohistochemical
images. Ten square regions of interest (ROIs) were selected
from the viable regions that showed [125I]IPOS accumulation on
each autoradiogram and were then transferred to the correspond-
ing immunohistochemical image. The positions of the ROIs
in both images were confirmed on the basis of the x- and
y-positions of each ROI that were displayed in both the soft-
wares. The quantification of radioactivity in each ROI and the
determination of the levels of HIF-1a expression and PIMO-
adduct formation were carried out according to the previously
reported method.(15)
Statistical analyses. Correlation coefficients were assessed
using Spearman’s rank analysis. A chi-square-test was used to
compare the correlation coefficients between [125I]IPOS-accu-
mulated areas and HIF-1a- or PIMO-positive areas. Values of
P < 0.05 were considered statistically significant.
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Results
In vivo and ex vivo SPECT ⁄CT imaging. Representative
SPECT ⁄CT images are shown in Figure 1. The images indi-
cate a clear and specific accumulation of radioactivity in the
FM3A tumor at 24 h after [125I]IPOS injection. Compared to
the tumor, there was no [125I]IPOS accumulation in the oppo-
site leg (Fig. 1A,B,D). The serial axial images documented
that the intratumoral distribution pattern of [125I]IPOS was
heterogeneous (Fig. 1E). The bladder can be seen in rostral-
side slices.
Figure 2 shows ex vivo SPECT images and corresponding
autoradiograms. Although autoradiograms showed intratumoral
distribution of [125I]IPOS in more detail due to its higher spatial
resolution than SPECT images, a similar distribution pattern of
[125I]IPOS was observed in both images. Staining with H&E
depicted necrotic regions in the tumor (Fig. 2, N), without the
accumulation of [125I]IPOS.
Ex vivo biodistribution. Table 1 shows the biodistribution of
[125I]IPOS in FM3A xenografts at 24 h after injection. A high
level of radioactivity was found to be accumulated in the liver
and intestine, and a moderate level was present in the kidneys
and tumor, and a low level was present in the muscle and neck.
The tumor accumulation was 1.7%ID ⁄g, the tumor ⁄blood ratio
was 5.6, and the tumor ⁄muscle ratio was 10. These results were
consistent with those of a previous report.(14)
Size-exclusion analysis of radioactive compounds in
tumors. The recovery of radioactivity from tumor homogenates
was 83% (SD, 3.8%). In the analysis using PD-10, most of the
radioactive material was eluted in macromolecular fractions
(77% [10%]). Moreover, by size-exclusion HPLC analysis,





Fig. 1. Representative single-photon emission computed tomography ⁄ computed tomography fusion images of FM3A-bearing mouse obtained
24 h after injection of [125I]IPOS. Maximum intensity projection (A), coronal (B), sagittal (C), and axial (D) images are shown. The arrow indicates
the tumor in the right thigh, and the arrowhead indicates the corresponding area in the opposite leg in (B). Serial axial images (slice thickness,
0.3 mm) are also shown in (E).
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the molecular weight of POS. In contrast, the radioactive mate-
rial in feces homogenates and urine was rarely eluted in macro-
molecular fractions (5.6% [3.0%] and 0.36% [0.06%],
respectively).
Autoradiography and immunohistochemistry. The autoradio-
gram represented that the distribution of [125I]IPOS in the tumor
was heterogeneous (Fig. 3A). Dual fluorescent immunohisto-
chemistry indicated the presence of HIF-1a- and PIMO-positive
hypoxic areas in the tumors (Fig. 3B,C). High-magnification
merged imaging of HIF-1a and PIMO immunostaining revealed
the presence of PIMO-positive areas along the edge of the HIF-
1a-positive areas. However, HIF-1a-positive areas and PIMO-
positive areas were not always identical. Some regions were
positive for both, whereas other regions did not overlap
(Fig. 3D). The majority of [125I]IPOS-accumulated areas corre-
sponded to the HIF-1a-positive areas (Fig. 3A,B).
We then compared correlations between [125I]IPOS accumu-
lation and HIF-1a or PIMO expression levels. As shown in Fig-
ure 4, areas with [125I]IPOS accumulation showed a positive
correlation with both HIF-1a- and PIMO-positive areas (HIF-
1a: R = 0.75, P < 0.0001; PIMO: R = 0.48, P = 0.0002). The
correlation coefficient between [125I]IPOS and HIF-1a was sig-
nificantly greater than that with PIMO (v2 = 8.38, P < 0.01).
Discussion
A number of hypoxia imaging probes, such as [18F]fluor-
omisonidazole ([18F]FMISO), 1-a-D-(5-deoxy-5-[18F]fluoroara-
binofuranosyl)-2-nitroimidazole ([18F]FAZA), and [60 ⁄ 64Cu]
Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([60 ⁄ 64Cu]Cu-ATSM),
have been developed and used in clinical studies.(20,21) These
probes detect physically low oxygen partial pressure
(<10 mmHg) and are useful for predicting the efficacy of radio-
therapy.(22) In fact, clinical PET studies with [60Cu]Cu-ATSM
have shown an inverse relationship between the tumor uptake of
[60Cu]Cu-ATSM and the response to therapy in patients with
lung and rectal carcinomas.(21) However, the mechanisms
underlying hypoxic accumulation of these probes are not depen-
dent on HIF-1 expression and further studies are necessary to
decisively determine the role of them in identifying HIF-1-
active regions in tumors.
The expression level of HIF-1a was reported to increase dra-
matically as the oxygen partial pressure decreased below
40 mmHg.(23) Furthermore, it was reported that the oxygen con-
centrations at which HIF-1 activity occurs differ among tissue
cells.(3,23) For example, pulmonary cells are consistently
exposed to relatively high oxygen concentrations, and thus, the
oxygen concentrations that these cells perceive as abnormal are
relatively high. However, bone marrow cells, which usually
exist under low oxygen concentrations, require no HIF-1 activity
when they are kept under the same oxygen concentrations as
pulmonary cells.(5) Therefore, probes that detect absolute physi-
cal oxygen partial pressures are not enough when attempting to
detect the expression or activity of HIF-1. Because HIF-1 is
associated with tumor progression, angiogenesis, metastasis, and
resistance to chemo- and radiotherapy, HIF-1 imaging would
provide significant information for characterizing tumor pheno-
type and would be useful for predicting prognosis. Thus, multi-
ple details on tumor characterization, treatment strategy, and
prognosis would be provided by linking [123I]IPOS-SPECT with
[18F]FMISO-, [18F]FAZA-, or [60 ⁄ 64Cu]Cu-ATSM-PET.
Recently, nuclear medical imaging(24–26) and bioluminescent
imaging(27,28) based on HIF-1-responsive reporter systems have
been successfully carried out. However, these systems required
exogenous gene transfection. To surmount this limitation, our
research group developed a number of injectable protein probes,
including [125I]IPOS, which contain ODD and degrade in an
oxygen-dependent manner. These probes have been used suc-
cessfully to visualize hypoxic tumors on planar nuclear medical
imaging(14,15) and optical imaging.(1,5,29) However, the in vivo
3D distribution of HIF-1-active regions in tumors has not been
extensively evaluated in our previous studies. Thus, we were
challenged to obtain high spatial resolution tomographic images
using multi-pinhole SPECT. Multi-pinhole SPECT systems have
recently provided greatly improved efficiency with high spatial
resolution and have overcome the resolution versus sensitivity




Fig. 2. Ex vivo single-photon emission computed tomography (SPECT) images with corresponding autoradiograms (ARG) and H&E stained
sections. The images were obtained 25.5 h after injection of [125I]IPOS. N, necrotic region.
Table 1. Biodistribution of [125I]IPOS at 24 h in FM3A-xenografted
mice (%ID ⁄ g)
Tissue Radioactivity
Blood 0.31 ± 0.03
Liver 15.93 ± 1.11
Intestine 6.34 ± 1.55
Kidneys 3.40 ± 1.54
Tumor 1.71 ± 0.26
Muscle 0.18 ± 0.04
Neck† 0.10 ± 0.02
Urine†‡ 45.85 ± 7.30
Feces†‡ 26.27 ± 10.71
Tumor ⁄ blood ratio 5.57 ± 1.01
Tumor ⁄muscle ratio 10.09 ± 2.82
Values are mean ± SD; n = 5. †Expressed as %ID. ‡n = 3.
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performance due to difficulties in attenuation and scattering
correction, and the sensitivity of multi-pinhole SPECT is still
lower than PET. However, because SPECT can theoretically
achieve a higher spatial resolution than PET, wherein the resolu-
tion is limited by the positron range, it is suitable for small
animal imaging. In fact, several multi-pinhole SPECT systems
are able to image small components within mouse organs.(31,32)
The in vivo images obtained in the present study were consistent
with the results of ex vivo biodistribution. The tumor was clearly
visualized, but no accumulation of radioactivity was observed in
the opposite leg (Fig. 1A,B,D), indicating a high tumor ⁄muscle
ratio (10 in ex vivo biodistribution). Our observation of high
radioactivity in the bladder (Fig. 1E) was in accordance with the
finding that the radioactivity was mainly excreted in urine after
the administration of [125I]IPOS.
The characterization of [125I]IPOS has been reported in a pre-
vious study.(14) Although the tumor uptake of [125I]IPOS was
significantly and positively correlated with HIF-1 transcriptional
activity, suggesting the feasibility of [125I]IPOS as an HIF-1-
active tumor imaging probe, a direct comparison between the in-
tratumoral distribution of [125I]IPOS and HIF-1 expression has
not yet been carried out. In the present study, the majority of the
[125I]IPOS-distributed areas in the tumor corresponded to HIF-
1a-positive hypoxic areas, although there were a few unmatched
regions (Fig. 3). A significant positive correlation was observed
between the areas, and the correlation coefficient between
[125I]IPOS and HIF-1a was significantly greater than that
between [125I]IPOS and PIMO (Fig. 4). Although we cannot
exclude the effect of the difference in the molecular sizes of
[125I]IPOS and PIMO on the distribution, these findings are con-
sistent with the results of recent studies showing that HIF-1a-
positive areas are not always colocalized with PIMO-positive
areas.(33–35) Thus, [125I]IPOS can be viewed as a probe that
depicts HIF-1-active areas rather than the physically hypoxic
areas themselves.
Although the detailed mechanism of cellular uptake and
retention of [125I]IPOS is now under investigation, we found that
low temperature (4C) or ATP depletion inhibited the cellular
uptake of [125I]IPOS (unpublished data). As most studies have
shown endocytosis as the major cellular uptake pathway for
most PTDs(36,37) and endocytosis occurs in an energy-dependent
manner, [125I]IPOS is probably uptaken by the cells through the
endocytotic pathway. After uptake by endocytosis, [125I]IPOS
could be released from the endosomes and retained intracellu-
larly because of its molecular size. In fact, in our previous
experiment, [125I]IPOS was not cleared from the cells under
hypoxic conditions for at least 24 h, after the incubation med-
ium was replaced with fresh medium.(14) Although the intra-
cellular radioactivity decreased gradually under normoxic
conditions, the cleared radioactivity was mainly attributable to
the small molecules.(14) These findings indicated the intracellu-
lar retention ability of [125I]IPOS.
(A) (B) (C) (D)
Fig. 3. Representative images of an autoradiogram (A), hypoxia-inducible factor (HIF)-1a immunostaining (B), and pimonidazole
immunostaining (C) in the identical section. A high-magnification merged image of HIF-1a immunostaining with pimonidazole immunostaining













































Fig. 4. Correlation between the intratumoral distribution of [125I]IPOS and the level of hypoxia-inducible factor (HIF)-1a expression (A) or that
of pimonidazole (PIMO)-adduct formation (B). The ordinate represents the percentage of HIF-1a- and PIMO-positive areas in each region of
interest (ROI), and the abscissa represents [125I]IPOS accumulation (%ID) in the same ROI. A total of 10 sections (two sections per tumor) were
analyzed. Regression analysis of the areas showing [125I]IPOS accumulation with HIF-1a- or PIMO-positive areas reveal a significantly positive
correlation in both cases (HIF-1a: R = 0.75, P < 0.0001; PIMO: R = 0.48, P = 0.0002). The results of the chi-square-test reveal that the correlation
coefficient between [125I]IPOS and HIF-1a was significantly higher than that between [125I]IPOS and PIMO (P < 0.01).
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In the present study, the biodistribution of [125I]IPOS was
consistent with a previous report;(14) thus, the reproducibility of
the biodistribution of [125I]IPOS was confirmed. Although the
amount of tumoral accumulation of [125I]IPOS was not as high
as that of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), this
could have been due to the limited expression of HIF-1. The
expression of HIF-1 is not ubiquitous, but heterogeneous, and is
small in tumors.(6) In fact, the probe accumulation in the tumors
harboring HIF-1-dependent reporter genes was 1–2%ID ⁄g in
previous studies,(6,38,39) which is comparable to the results of the
present study. The size-exclusion analysis revealed that the
radioactivity in the tumor existed as 34-kDa macromolecules
that were most likely [125I]IPOS existing stably in hypoxic
regions. Furthermore, the radioactivity in urine and feces were
mainly in low-molecular-weight compounds. This was consis-
tent with our previous in vitro findings showing that [125I]IPOS
was degraded in normoxic cells and that [125I]IBB and other
small molecules were cleared from the cells.(14) Thus, these
findings prove the concept of [125I]IPOS in vivo and show that
[125I]IPOS exists stably only in the HIF-1-active regions while
undergoing degradation and clearance in normoxic regions.
Although HIF-1a was reported to degrade within a few min-
utes under normoxic conditions,(5) the degradation of [125I]IPOS
was relatively slow.(14) Thus, a long exposure time is necessary
to obtain sufficiently contrasting images; this is one of the draw-
backs of [125I]IPOS. Moreover, a study has shown that the acute
hypoxic region created by the shutdown of blood vessels can be
reoxygenated after reopening the blood vessels.(40) In such reox-
ygenated areas especially, the inconsistency in the rates of deg-
radation of HIF-1a and [125I]IPOS may be responsible for the
differences in the distribution pattern of [125I]IPOS and HIF-1a
expression. POS comprises not only the ODD, which is the
essential domain related to oxygen-dependent degradation, but
also the PTD and SAV. This modification may hamper the
degradation of the probe. However, this is not a substantial
problem; a pretargeting approach can overcome this drawback.
In fact, a 4–8-fold earlier visualization of the tumor can be
achieved with the SAV–radiolabeled biotin-based pretargeting
approach.(15,18)
In conclusion, multi-pinhole high-resolution SPECT ⁄CT
imaging with [125I]IPOS clearly visualized a tumor. The
obtained images were in accordance with the corresponding
autoradiograms and the analysis of ex vivo biodistribution. The
autoradiograms documented that the intratumoral distribution of
[125I]IPOS was heterogeneous and showed a good correlation
with HIF-1a-positive areas. These findings indicate that the dis-
tribution of [125I]IPOS reflects the expression of HIF-1a, thus
rendering [123 ⁄ 125I]IPOS an effective probe for the molecular
imaging of HIF-1-active tumors.
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